Emerging Markets Earnings Roundup: Roche, Lilly, Bristol Myers Squibb (Part 2)
This article was originally published in PharmAsia News
Executive Summary
China remains the star in emerging markets, with Roche reporting 26% growth in China for pharma and 19% in diagnostics, and Eli Lilly & Co. reporting 18% growth in China. Bristol-Myers Squibb Co. had little to report on EMs, but it signed a manufacturing agreement with South Korea’s Samsung BioLogics for an undisclosed cancer drug.
You may also be interested in...
Earnings Briefs: Actavis, Celgene, InterMune, Lilly, Forest
Companies are reporting out their half-year earnings and giving investors updates on the progress of their pipelines, as well as ongoing launch plans. Actavis and Warner Chilcott are in line as their merger approaches; Lilly’s Lechleiter gives an update on BD plans; AbbVie talks about its HCV combo; and Shire recommits to ADHD promotion.
Roche Follow-On Development Strategy Highlighted By Strong 1H Results
Top oncology specialist Roche’s second quarter saw robust sales growth with new breast cancer medicines Perjeta and Kadcyla selling well, highlighting and further validating its strategy to develop follow-on drugs to replace or renew older treatments while expanding into new disease areas.
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.